Crescendo Bioscience, a wholly-owned subsidiary of Myriad Genetics, Inc. (Nasdaq: MYGN), today announced the online publication of a new study in the journalAnnals of the Rheumatic Diseases for Crescendo’s Vectra DA blood test.

Click Here to read more